Walk into any pharmacy in India today and there is a decent chance the chemist behind the counter is worried. Not about stock, not about margins — about a smartphone app that is quietly pulling his customers away.
Ten years ago, online pharmacies barely existed in India. The market had over 850,000 brick-and-mortar chemist shops, all operating the same way they had for decades — a neighbourhood counter, a relationship with a local stockist, and an understanding that patients would keep coming back because they had no real alternative.
That assumption is no longer safe. And understanding how it broke — and what replaced it — tells you a lot about where this industry is going.
How it actually started
The first wave of e-pharmacies around 2015 was underwhelming. These were essentially mail-order services — you uploaded a prescription, they posted your medicines. Limited internet access, low consumer trust, and the sheer habit of walking to the local chemist meant adoption was slow. The industry sat at roughly 2% of the total pharma retail market and nobody was particularly alarmed.
What changed everything was not a single company or a single product. It was infrastructure. Cheap smartphones flooded the market. Reliance Jio made mobile data practically free. The government's Digital India push and Ayushman Bharat Digital Mission brought millions of first-time internet users online. By 2020, the conditions that had kept e-pharmacies marginal had quietly disappeared.
Then the pandemic hit.
Lockdowns shut physical retail. Patients with chronic conditions — diabetes, hypertension, thyroid — could not get to their pharmacies. At the exact moment demand for medicines surged, supply chains for traditional retail broke down. The Ministry of Health responded by invoking Section 26B of the Drugs and Cosmetics Act, 1940, which temporarily authorised all pharmacies to deliver prescription medicines to doorsteps and allowed prescriptions to be submitted digitally via email.
That emergency order lasted months. The habit it created has lasted years. Household e-pharmacy adoption multiplied 2.5 times during the pandemic window alone. Platforms like Tata 1mg, PharmEasy, Netmeds, and Apollo 24/7 scaled faster than anyone had projected. What had been a convenience became a routine — and routines are hard to break.
By the time restrictions lifted, the industry had compounded at 30 to 40 percent annually and was valued in the billions. The 2% niche was gone. Something structurally different had taken its place.
The four ways e-pharmacies actually work
One thing that gets lost in coverage of this industry is that "e-pharmacy" is not one business model — it is at least four. And they work very differently from each other.
The inventory model
The platform owns warehouses, stocks medicines directly, employs registered pharmacists, and ships from its own fulfilment hubs. Higher capital required, but total control over quality, cold chain, and margin. Tata 1mg operates largely this way. The tradeoff is that you need serious upfront investment before you can serve a single order.
The marketplace model
The platform is a technology layer — it connects consumers to licensed local pharmacies, routes the order, processes payment, and takes a commission. No inventory owned, no warehouses needed. Highly scalable and capital-light. The problem is consistency. When you are routing through hundreds of independent pharmacies, prescription verification and delivery timelines become genuinely difficult to control.
The hybrid model
Large conglomerates — Apollo being the clearest example — have merged online and offline by acquiring or building physical storefronts that double as local fulfilment centres. The consumer books online, a nearby store dispatches in under two hours. This solves the last-mile problem and also addresses something no app UI can fully replace: the consumer's trust in a physical counter they can walk back into if something goes wrong.
The B2B model
The less visible but increasingly important play. E-pharmacy platforms have built wholesale distribution arms that supply local pharmacies, clinics, and diagnostic labs directly from manufacturers. By aggregating demand and sourcing at scale, they can undercut regional stockists on price. This is quietly dismantling supply structures that have been in place for decades.
Each model requires a different commercial skill set. If you end up at a platform like PharmEasy or Tata 1mg, understanding which model they run — and what its constraints are — explains almost every commercial decision they make.
Why consumers actually switched — and it is not what you think
The obvious answer is price. E-pharmacies typically offer 10 to 20 percent discounts versus MRP — driven by direct sourcing and thinner intermediary chains. And yes, price matters in a market where most people pay out of pocket and medicines consume a significant share of household health spending.
But price alone does not explain stickiness. Research applying the Theory of Consumption Value to Indian e-pharmacy users found something more interesting: price reasonability, as an isolated variable, showed no statistically significant relationship with purchase intent.
What actually drives continued use is perceived safety — the confidence that the platform is supplying authentic, unadulterated medicines with proper pharmacist oversight. When a platform earns that trust, retention follows almost automatically. When it does not, no discount is large enough to compensate.
There is also a social dimension that is easy to underestimate. In urban and semi-urban India, using a health tech platform — tracking your orders, managing your prescriptions digitally, booking diagnostic tests through an app — carries a certain social signal. It positions you as someone who manages their health proactively. That perception, however intangible, is a real driver of adoption.
The insight is counterintuitive: people do not stay on e-pharmacies primarily because they are cheaper. They stay because the platform has made them feel their medicines are safe. Price brought them in. Safety keeps them.
What this did to traditional chemists
For decades, brick-and-mortar pharmacy retail in India operated under a cartelised structure. The All India Organisation of Chemists and Druggists — AIOCD — controlled market supply through agreements that required pharmaceutical companies to get a No Objection Certificate from local trade associations before appointing any new stockist. If a stockist tried to offer independent discounts or bypass association pricing, organised boycotts cut off their distribution.
The Competition Commission of India investigated and documented these practices repeatedly. But the cartel survived because there was no alternative distribution channel. You needed the local stockist, which meant you needed the association's approval.
E-pharmacies broke this by aggregating demand at a national level and sourcing directly from manufacturers. Regional stockists became optional. The enforcement mechanism of local associations collapsed.
The retail response was immediate and measurable. Survey data shows that 43 percent of traditional retail pharmacists reported an immediate drop in foot traffic, and 24 percent had to directly reduce prices to retain customers. These are not small numbers for businesses that were already operating on thin margins.
But the more interesting response has been adaptation. Over 52 percent of local pharmacies are now implementing some form of digital system — WhatsApp ordering, SaaS-based inventory management, home delivery partnerships. The neighbourhood chemist is not disappearing. They are being forced to become something different — which also means the trade margin structures that traditionally kept them loyal to certain brands are under pressure in a way they have never been before.
The problems nobody talks about
E-pharmacies have created real convenience and genuinely improved access to medicines in Tier 2 and Tier 3 cities where specialist pharmacies barely existed. But they have also introduced problems that are serious and not being addressed fast enough.
The prescription recycler loophole
In a physical pharmacy, when you hand over a prescription, the pharmacist stamps or marks it. You cannot use that prescription again. Digital platforms stripped this safeguard away. When a consumer uploads a photo of a prescription, the underlying paper is never marked. The same image can be uploaded to multiple platforms — or to the same platform again months later.
Research confirms that only 24 percent of consumers are consistently required to upload a valid prescription across all online purchases. Thirty-nine percent report being asked only sometimes. This creates a real and open route to Schedule H and H1 medications — corticosteroids, tranquilisers, psychotropic compounds — without meaningful oversight.
Antimicrobial resistance
The ease of online access, combined with teleconsultation checkboxes that are more formality than review, has driven a measurable increase in antibiotic self-medication. Clinicians call this digital iatrogenesis — harm caused not by a drug itself but by the absence of a proper clinical evaluation before prescribing it. When patients use recycled prescriptions, self-diagnose through internet searches, and access antibiotics without examination, the consequences compound over time into antimicrobial resistance patterns that affect everyone.
The regulation that never arrived
Here is the part that should concern anyone studying Indian pharma as a career: the regulatory framework for e-pharmacies does not exist. The same CDSCO that is now enforcing Schedule M compliance across manufacturers has never formally licensed a single e-pharmacy.
The laws currently governing medicine distribution in India — the Drugs and Cosmetics Act, 1940 and the Pharmacy Act, 1948 — were written to regulate physical facilities. They contain no definitions for online platforms, no provisions for digital prescriptions, no licensing path for e-pharmacies.
The Ministry of Health drafted the E-Pharmacy Rules in August 2018. The framework was sensible: mandatory registration under the DCGI, strict data localisation rules, a ban on advertising prescription drugs, 24/7 customer support requirements. It was released for public comment. And then, under sustained lobbying pressure from traditional trade associations, it stalled. Seven years later, it has still not been notified into law.
The result is a legal grey zone that nobody is comfortable in. Courts have issued interim bans on online drug sales — then stayed those bans when patients who rely on home delivery complained. The CDSCO issued show-cause notices to 20 major platforms in 2023 for dispensing prescription drugs without proper oversight. Platforms responded by claiming intermediary safe harbour under the Information Technology Act, arguing they are marketplaces, not pharmacies, and therefore not responsible for what their users transact.
India's e-pharmacy industry is a multi-billion dollar sector operating without a legal framework specifically written for it. Every major platform is making commercial decisions inside regulatory uncertainty. That uncertainty is not going away quickly.
What this means for you
If you end up in digital health, brand management, or commercial roles at a pharma company, understanding e-pharmacies is no longer optional. These platforms are becoming a primary channel — not a secondary one. How you price, how you manage trade margins, how you think about prescription vs OTC marketing, all of it is being recalibrated around digital distribution.
If you end up in regulatory or government affairs, the E-Pharmacy Rules represent one of the most consequential unfinished pieces of legislation in Indian pharma. Whoever helps navigate that framework into law — or helps companies operate compliantly within whatever form it takes — will be doing genuinely important work.
And if you end up in pharmacy practice, the transition happening right now is not optional to engage with. The question is not whether digital distribution will reshape your profession. It already has. The question is what role you want to play in what comes next.
If this was useful, the next piece worth reading is on how drugs are priced in India — which covers the DPCO mechanics and trade margin structures that sit behind why e-pharmacies can offer consistent discounts without necessarily running at a loss.